Influence of RANKL inhibition on immune system in the treatment of bone diseases
Authors:
- Anne Fouque-AubertAFAnne Fouque-Aubert
- Roland ChapurlatRCRoland Chapurlat
- 1 January 2008
- journal article
- review article
- Published by Elsevier in Joint Bone Spine
- Vol. 75 (1) , 5-10
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- TNF-α antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritisBone, 2004
- A Novel in Vivo Role for Osteoprotegerin Ligand in Activation of Monocyte Effector Function and Inflammatory ResponseJournal of Biological Chemistry, 2004
- Biology of the TRANCE axisCytokine & Growth Factor Reviews, 2003
- Trance, a Tumor Necrosis Factor Family Member, Enhances the Longevity and Adjuvant Properties of Dendritic Cells in VivoJournal of Experimental Medicine, 2000
- Inherited Human Caspase 10 Mutations Underlie Defective Lymphocyte and Dendritic Cell Apoptosis in Autoimmune Lymphoproliferative Syndrome Type IICell, 1999
- Receptor activator of NF‐κB recruits multiple TRAF family adaptors and activates c‐Jun N‐terminal kinaseFEBS Letters, 1999
- RANK Is the Essential Signaling Receptor for Osteoclast Differentiation Factor in OsteoclastogenesisBiochemical and Biophysical Research Communications, 1998
- Isolation and characterization of osteoclast precursors that differentiate into osteoclasts on calvarial cells within a short period of timeJournal of Cellular Physiology, 1998
- Osteoprotegerin Production by Human Osteoblast Lineage Cells Is Stimulated by Vitamin D, Bone Morphogenetic Protein-2, and CytokinesBiochemical and Biophysical Research Communications, 1998
- Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and ActivationCell, 1998